What you should know:
1. Researchers tested BT-11 in 70 patients as either a single-ascending dose or as a seven-day multiple-ascending dose.
2. Fecal concentrations of BT-11 were 6,000 times higher than maximum plasma concentrations. Researchers said the increased concentrations mirrored what they observed in preclinical animal tests.
3. Landos will explore the seven-day, 14 milligram dosage in a phase 2 clinical trial.
More articles on gastroenterology:
3 things to know about outpatient cervical disc replacement
10 things to know about spine surgery for ASCs in 2019
Outpatient revision minimally invasive lumbar decompression: 4 notes on ASC vs. HOPD
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
